Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

enitociclib , CAS No.1610408-97-3, Inhibitor of cyclin dependent kinase 9

Item Number
E610134
Grouped product items
SKUSizeAvailabilityPrice Qty
E610134-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$270.90
E610134-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$940.90

Basic Description

SynonymsEnitociclib [WHO-DD] | 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-(4-(((S(S))-S-methylsulfonimidoyl)methyl)-2-pyridinyl)- | 2-Pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[[[S(S)]-S-methylsulfonimidoyl]methyl]-2-pyridinyl]- | ENIT
Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of cyclin dependent kinase 9

AI Insight

Associated Targets(Human)

CDK9 Tchem Cyclin-dependent kinase 9 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CCNE1 Tchem Cyclin-dependent kinase 2/cyclin E1 (1877 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

The page will load shortly, Thanks for your patience!
Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
INCHI InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1
InChi Key YZCUMZWULWOUMD-NDEPHWFRSA-N
Canonical SMILES COc1cc(F)ccc1c1cc(Nc2cc(C[S@@](=N)(=O)C)ccn2)ncc1F
Isomeric SMILES COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)C[S@@](=N)(=O)C
PubChem CID 139593425

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Related Documents

Reviews

Customer Reviews

No reviews here yet. Be the first to write one!

References

1. Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U et al..  (2021)  Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer..  J Med Chem,  64  (15): (11651-11674).  [PMID:34264057] [10.1021/op500134e]

Solution Calculators